CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 721 enrolled
Drug / intervention
insulin degludec +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

In the news

1 article

Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.

Search/NCT02030600
NCT02030600Phase 3Completed
CompareCT.gov

A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Novo Nordisk A/S·interventional·Posted Jan 8, 2014·Updated May 10, 2019

In Brief

A Phase 3 clinical trial evaluating insulin degludec and insulin glargine for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 721 participants across 166 sites in 2 countries.

Detailed Summary

This trial is conducted in the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar) with or without OADs (oral anti-diabetic drugs) excluding SUs (sulfonylureas)/glinides in subjects with type 2 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 8, 2014
Enrollment StartJan 6, 2014
Primary CompletionDec 4, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.5 years ago

Interventions

insulin degludecdrug

Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

insulin glarginedrug

Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.